Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erik Hermansson

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
The FEBS Journal|June 15, 2011
BRICHOS domain associated with lung fibrosis, dementia and cancer--a chaperone that prevents amyloid fibril formation?Hanna Willander, Erik Hermansson, Jan Johansson, et al.
Statistics in Medicine|January 22, 2026
Overview and Practical Recommendations on Using Shapley Values for Identifying Predictive Biomarkers via CATE ModelingDavid Svensson, Erik Hermansson, Nikolaos Nikolaou, et al.
Pharmaceutical Statistics|March 4, 2024
Digital twins and Bayesian dynamic borrowing: Two recent approaches for incorporating historical control dataCarl-Fredrik Burman, Erik Hermansson, David Bock, et al.
Disease Models & Mechanisms|April 1, 2014
The chaperone domain BRICHOS prevents CNS toxicity of amyloid-β peptide in Drosophila melanogasterErik Hermansson, Sebastian Schultz, Damian Crowther, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 7, 2018
BRICHOS domain of Bri2 inhibits islet amyloid polypeptide (IAPP) fibril formation and toxicity in human beta cellsMarie E Oskarsson, Erik Hermansson, Ye Wang, et al.
Biochimica Et Biophysica Acta|April 21, 2015
Dissociation of a BRICHOS trimer into monomers leads to increased inhibitory effect on Aβ42 fibril formationHenrik Biverstål, Lisa Dolfe, Erik Hermansson, et al.
BMJ Open Respiratory Research|March 6, 2026
Efficacy and safety of as-needed albuterol-budesonide versus albuterol in patients with asthma aged 12 to <18 years: design of the randomised, double-blind, parallel-group phase IIIb ACADIA trialLeonard Benjamin Bacharier, Hengameh Raissy, Samuel Bardsley, et al.
The Biochemical Journal|August 13, 2016
Dementia-related Bri2 BRICHOS is a versatile molecular chaperone that efficiently inhibits Aβ42 toxicity in DrosophilaHelen Poska, Martin Haslbeck, Firoz Roshan Kurudenkandy, et al.
Current Medical Research and Opinion|August 16, 2023
Mortality risk reduction with budesonide/glycopyrrolate/formoterol fumarate versus fluticasone furoate/umeclidinium/vilanterol in COPD: a matching-adjusted indirect comparison based on ETHOS and IMPACTDaiana Stolz, Erik Hermansson, Mario Ouwens, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 23, 2011
Heparan sulfate/heparin promotes transthyretin fibrillization through selective binding to a basic motif in the proteinFredrik Noborn, Paul O'Callaghan, Erik Hermansson, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
The FEBS Journal|June 15, 2011
BRICHOS domain associated with lung fibrosis, dementia and cancer--a chaperone that prevents amyloid fibril formation?Hanna Willander, Erik Hermansson, Jan Johansson, et al.
Statistics in Medicine|January 22, 2026
Overview and Practical Recommendations on Using Shapley Values for Identifying Predictive Biomarkers via CATE ModelingDavid Svensson, Erik Hermansson, Nikolaos Nikolaou, et al.
Pharmaceutical Statistics|March 4, 2024
Digital twins and Bayesian dynamic borrowing: Two recent approaches for incorporating historical control dataCarl-Fredrik Burman, Erik Hermansson, David Bock, et al.
Disease Models & Mechanisms|April 1, 2014
The chaperone domain BRICHOS prevents CNS toxicity of amyloid-β peptide in Drosophila melanogasterErik Hermansson, Sebastian Schultz, Damian Crowther, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 7, 2018
BRICHOS domain of Bri2 inhibits islet amyloid polypeptide (IAPP) fibril formation and toxicity in human beta cellsMarie E Oskarsson, Erik Hermansson, Ye Wang, et al.
Biochimica Et Biophysica Acta|April 21, 2015
Dissociation of a BRICHOS trimer into monomers leads to increased inhibitory effect on Aβ42 fibril formationHenrik Biverstål, Lisa Dolfe, Erik Hermansson, et al.
BMJ Open Respiratory Research|March 6, 2026
Efficacy and safety of as-needed albuterol-budesonide versus albuterol in patients with asthma aged 12 to <18 years: design of the randomised, double-blind, parallel-group phase IIIb ACADIA trialLeonard Benjamin Bacharier, Hengameh Raissy, Samuel Bardsley, et al.
The Biochemical Journal|August 13, 2016
Dementia-related Bri2 BRICHOS is a versatile molecular chaperone that efficiently inhibits Aβ42 toxicity in DrosophilaHelen Poska, Martin Haslbeck, Firoz Roshan Kurudenkandy, et al.
Current Medical Research and Opinion|August 16, 2023
Mortality risk reduction with budesonide/glycopyrrolate/formoterol fumarate versus fluticasone furoate/umeclidinium/vilanterol in COPD: a matching-adjusted indirect comparison based on ETHOS and IMPACTDaiana Stolz, Erik Hermansson, Mario Ouwens, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 23, 2011
Heparan sulfate/heparin promotes transthyretin fibrillization through selective binding to a basic motif in the proteinFredrik Noborn, Paul O'Callaghan, Erik Hermansson, et al.
Pageof 2